Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs.

Christmas BJ, Rafie CI, Hopkins AC, Scott BA, Ma HS, Cruz KA, Woolman S, Armstrong TD, Connolly RM, Azad NA, Jaffee EM, Roussos Torres ET.

Cancer Immunol Res. 2018 Oct 19. pii: canimm.0070.2018. doi: 10.1158/2326-6066.CIR-18-0070. [Epub ahead of print]

PMID:
30341213
2.

Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.

Kinkead HL, Hopkins A, Lutz E, Wu AA, Yarchoan M, Cruz K, Woolman S, Vithayathil T, Glickman LH, Ndubaku CO, McWhirter SM, Dubensky TW Jr, Armstrong TD, Jaffee EM, Zaidi N.

JCI Insight. 2018 Oct 18;3(20). pii: 122857. doi: 10.1172/jci.insight.122857. [Epub ahead of print]

3.

Emerging strategies for combination checkpoint modulators in cancer immunotherapy.

Popovic A, Jaffee EM, Zaidi N.

J Clin Invest. 2018 Aug 1;128(8):3209-3218. doi: 10.1172/JCI120775. Epub 2018 Aug 1. Review.

4.

T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.

Hopkins AC, Yarchoan M, Durham JN, Yusko EC, Rytlewski JA, Robins HS, Laheru DA, Le DT, Lutz ER, Jaffee EM.

JCI Insight. 2018 Jul 12;3(13). pii: 122092. doi: 10.1172/jci.insight.122092. [Epub ahead of print]

5.

Stromal Annexin A2 expression is predictive of decreased survival in pancreatic cancer.

Murphy AG, Foley K, Rucki AA, Xia T, Jaffee EM, Huang CY, Zheng L.

Oncotarget. 2017 Nov 15;8(63):106405-106414. doi: 10.18632/oncotarget.22433. eCollection 2017 Dec 5.

6.

Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

Yarchoan M, Hopkins A, Jaffee EM.

N Engl J Med. 2017 Dec 21;377(25):2500-2501. doi: 10.1056/NEJMc1713444. No abstract available.

7.

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A.

Lancet Oncol. 2017 Nov;18(11):e653-e706. doi: 10.1016/S1470-2045(17)30698-8. Epub 2017 Oct 31. Review.

8.

Report on the Third FDA-AACR Oncology Dose-Finding Workshop.

Emens LA, Bruno R, Rubin EH, Jaffee EM, McKee AE.

Cancer Immunol Res. 2017 Dec;5(12):1058-1061. doi: 10.1158/2326-6066.CIR-17-0590.

PMID:
29196440
9.

Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy.

Rao AD, Liu Y, von Eyben R, Hsu CC, Hu C, Rosati LM, Parekh A, Ng K, Hacker-Prietz A, Zheng L, Pawlik TM, Laheru DA, Jaffee EM, Weiss MJ, Le DT, Hruban RH, De Jesus-Acosta A, Wolfgang CL, Narang AK, Chang DT, Koong AC, Herman JM.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):486-489. doi: 10.1016/j.ijrobp.2017.10.001. Epub 2017 Oct 12.

PMID:
29157747
10.

Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective.

Ryan JF, Groot VP, Rosati LM, Hacker-Prietz A, Narang AK, McNutt TR, Jackson JF, Le DT, Jaffee EM, Zheng L, Laheru DA, He J, Pawlik TM, Weiss MJ, Wolfgang CL, Herman JM.

Ann Surg Oncol. 2018 Jan;25(1):280-289. doi: 10.1245/s10434-017-6134-6. Epub 2017 Oct 23.

PMID:
29063299
11.

A Blueprint to Advance Colorectal Cancer Immunotherapies.

Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA Jr, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, Kang SP, Krishnamurthi SS, Lieu CH, Messersmith W, Sears CL, Segal NH, Yang A, Moss RA, Cha E, O'Donnell-Tormey J, Roach N, Davis AQ, McAbee K, Worrall S, Benson AB.

Cancer Immunol Res. 2017 Nov;5(11):942-949. doi: 10.1158/2326-6066.CIR-17-0375. Epub 2017 Oct 16.

12.

Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.

Yarchoan M, Xing D, Luan L, Xu H, Sharma RB, Popovic A, Pawlik TM, Kim AK, Zhu Q, Jaffee EM, Taube JM, Anders RA.

Clin Cancer Res. 2017 Dec 1;23(23):7333-7339. doi: 10.1158/1078-0432.CCR-17-0950. Epub 2017 Sep 19.

13.

Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.

Zloza A, Karolina Palucka A, Coussens LM, Gotwals PJ, Headley MB, Jaffee EM, Lund AW, Sharpe AH, Sznol M, Wainwright DA, Wong KK, Bosenberg MW.

J Immunother Cancer. 2017 Sep 19;5(1):77. doi: 10.1186/s40425-017-0278-6.

14.

Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment.

Rucki AA, Xiao Q, Muth S, Chen J, Che X, Kleponis J, Sharma R, Anders RA, Jaffee EM, Zheng L.

Mol Cancer Ther. 2017 Nov;16(11):2399-2409. doi: 10.1158/1535-7163.MCT-16-0452. Epub 2017 Sep 1.

15.

Targeting neoantigens to augment antitumour immunity.

Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM.

Nat Rev Cancer. 2017 Aug 24;17(9):569. doi: 10.1038/nrc.2017.74. No abstract available.

PMID:
28835723
16.

Immune Modulation Therapy and Imaging: Workshop Report.

Shields AF, Jacobs PM, Sznol M, Graham MM, Germain RN, Lum LG, Jaffee EM, de Vries EGE, Nimmagadda S, Van den Abbeele AD, Leung DK, Wu AM, Sharon E, Shankar LK.

J Nucl Med. 2018 Mar;59(3):410-417. doi: 10.2967/jnumed.117.195610. Epub 2017 Aug 17.

17.

A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.

Foote JB, Kok M, Leatherman JM, Armstrong TD, Marcinkowski BC, Ojalvo LS, Kanne DB, Jaffee EM, Dubensky TW Jr, Emens LA.

Cancer Immunol Res. 2017 Jun;5(6):468-479. doi: 10.1158/2326-6066.CIR-16-0284. Epub 2017 May 8.

18.

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.

Yarchoan M, Myzak MC, Johnson BA 3rd, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M.

Oncotarget. 2017 Jul 4;8(27):44073-44081. doi: 10.18632/oncotarget.17237.

19.

Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis.

Tsujikawa T, Kumar S, Borkar RN, Azimi V, Thibault G, Chang YH, Balter A, Kawashima R, Choe G, Sauer D, El Rassi E, Clayburgh DR, Kulesz-Martin MF, Lutz ER, Zheng L, Jaffee EM, Leyshock P, Margolin AA, Mori M, Gray JW, Flint PW, Coussens LM.

Cell Rep. 2017 Apr 4;19(1):203-217. doi: 10.1016/j.celrep.2017.03.037.

20.

Strategies for Increasing Pancreatic Tumor Immunogenicity.

Johnson BA 3rd, Yarchoan M, Lee V, Laheru DA, Jaffee EM.

Clin Cancer Res. 2017 Apr 1;23(7):1656-1669. doi: 10.1158/1078-0432.CCR-16-2318. Review.

21.

Targeting neoantigens to augment antitumour immunity.

Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM.

Nat Rev Cancer. 2017 Apr;17(4):209-222. doi: 10.1038/nrc.2016.154. Epub 2017 Feb 24. Review. Erratum in: Nat Rev Cancer. 2017 Aug 24;17 (9):569.

22.

Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, Pastan I.

J Clin Oncol. 2016 Dec;34(34):4171-4179. Epub 2016 Oct 31. Review.

23.

Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer.

Rucki AA, Foley K, Zhang P, Xiao Q, Kleponis J, Wu AA, Sharma R, Mo G, Liu A, Van Eyk J, Jaffee EM, Zheng L.

Cancer Res. 2017 Jan 1;77(1):41-52. doi: 10.1158/0008-5472.CAN-16-1383. Epub 2016 Nov 7.

24.

Leveraging premalignant biology for immune-based cancer prevention.

Spira A, Disis ML, Schiller JT, Vilar E, Rebbeck TR, Bejar R, Ideker T, Arts J, Yurgelun MB, Mesirov JP, Rao A, Garber J, Jaffee EM, Lippman SM.

Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):10750-8. doi: 10.1073/pnas.1608077113. Epub 2016 Sep 16.

25.

De novo DNA methylation by DNA methyltransferase 3a controls early effector CD8+ T-cell fate decisions following activation.

Ladle BH, Li KP, Phillips MJ, Pucsek AB, Haile A, Powell JD, Jaffee EM, Hildeman DA, Gamper CJ.

Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10631-6. doi: 10.1073/pnas.1524490113. Epub 2016 Aug 31.

26.

Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methylation.

Xiao Q, Zhou D, Rucki AA, Williams J, Zhou J, Mo G, Murphy A, Fujiwara K, Kleponis J, Salman B, Wolfgang CL, Anders RA, Zheng S, Jaffee EM, Zheng L.

Cancer Res. 2016 Sep 15;76(18):5395-404. doi: 10.1158/0008-5472.CAN-15-3264. Epub 2016 Aug 5.

27.

Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.

Wild AT, Herman JM, Dholakia AS, Moningi S, Lu Y, Rosati LM, Hacker-Prietz A, Assadi RK, Saeed AM, Pawlik TM, Jaffee EM, Laheru DA, Tran PT, Weiss MJ, Wolfgang CL, Ford E, Grossman SA, Ye X, Ellsworth SG.

Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):571-9. doi: 10.1016/j.ijrobp.2015.11.026. Epub 2015 Dec 1.

28.

Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer.

Jhaveri DT, Kim MS, Thompson ED, Huang L, Sharma R, Klein AP, Zheng L, Le DT, Laheru DA, Pandey A, Jaffee EM, Anders RA.

Cancer Immunol Res. 2016 Mar;4(3):225-33. doi: 10.1158/2326-6066.CIR-15-0200-T. Epub 2016 Feb 3. Erratum in: Cancer Immunol Res. 2016 May;4(5):472.

29.

TGF-╬▓ blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner.

Soares KC, Rucki AA, Kim V, Foley K, Solt S, Wolfgang CL, Jaffee EM, Zheng L.

Oncotarget. 2015 Dec 15;6(40):43005-15. doi: 10.18632/oncotarget.5656.

30.

Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer.

Foley K, Rucki AA, Xiao Q, Zhou D, Leubner A, Mo G, Kleponis J, Wu AA, Sharma R, Jiang Q, Anders RA, Iacobuzio-Donahue CA, Hajjar KA, Maitra A, Jaffee EM, Zheng L.

Sci Signal. 2015 Aug 4;8(388):ra77. doi: 10.1126/scisignal.aaa5823.

31.

Special Conference on Tumor Immunology and Immunotherapy: A New Chapter.

Byrne KT, Vonderheide RH, Jaffee EM, Armstrong TD.

Cancer Immunol Res. 2015 Jun;3(6):590-597. doi: 10.1158/2326-6066.CIR-15-0106. Epub 2015 May 12.

32.

Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy.

Lutz ER, Kinkead H, Jaffee EM, Zheng L.

Oncoimmunology. 2014 Dec 21;3(11):e962401. eCollection 2014 Nov.

33.

Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention.

Chu NJ, Armstrong TD, Jaffee EM.

Clin Cancer Res. 2015 Apr 1;21(7):1549-57. doi: 10.1158/1078-0432.CCR-14-1186. Epub 2015 Jan 26. Review.

34.

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM.

J Clin Oncol. 2015 Apr 20;33(12):1325-33. doi: 10.1200/JCO.2014.57.4244. Epub 2015 Jan 12.

35.

Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer.

Jhaveri DT, Zheng L, Jaffee EM.

Semin Oncol. 2014 Oct;41(5):559-75. doi: 10.1053/j.seminoncol.2014.07.001. Epub 2014 Jul 22. Review.

36.

PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.

Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, Wamwea A, Bigelow E, Lutz E, Liu L, Yao S, Anders RA, Laheru D, Wolfgang CL, Edil BH, Schulick RD, Jaffee EM, Zheng L.

J Immunother. 2015 Jan;38(1):1-11. doi: 10.1097/CJI.0000000000000062.

37.

The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy.

Bever KM, Sugar EA, Bigelow E, Sharma R, Laheru D, Wolfgang CL, Jaffee EM, Anders RA, De Jesus-Acosta A, Zheng L.

HPB (Oxford). 2015 Apr;17(4):292-8. doi: 10.1111/hpb.12334. Epub 2014 Sep 23.

38.

Cancer immunoprevention--the next frontier.

Smit MA, Jaffee EM, Lutz ER.

Cancer Prev Res (Phila). 2014 Nov;7(11):1072-80. doi: 10.1158/1940-6207.CAPR-14-0178. Epub 2014 Sep 22. Review.

39.

A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.

Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram JN, Dauses T, Fetting J, Duus EM, Atay-Rosenthal S, Ye X, Wolff AC, Stearns V, Jaffee EM, Emens LA.

Cancer Immunol Res. 2014 Oct;2(10):949-61. doi: 10.1158/2326-6066.CIR-14-0058. Epub 2014 Aug 12.

40.

PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition.

Zhou W, Jubb AM, Lyle K, Xiao Q, Ong CC, Desai R, Fu L, Gnad F, Song Q, Haverty PM, Aust D, Gr├╝tzmann R, Romero M, Totpal K, Neve RM, Yan Y, Forrest WF, Wang Y, Raja R, Pilarsky C, de Jesus-Acosta A, Belvin M, Friedman LS, Merchant M, Jaffee EM, Zheng L, Koeppen H, Hoeflich KP.

J Pathol. 2014 Dec;234(4):502-13. doi: 10.1002/path.4412. Epub 2014 Oct 6.

41.

A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer.

Zheng L, Edil BH, Soares KC, El-Shami K, Uram JN, Judkins C, Zhang Z, Onners B, Laheru D, Pardoll D, Jaffee EM, Schulick RD.

Ann Surg Oncol. 2014 Nov;21(12):3931-7. doi: 10.1245/s10434-014-3844-x. Epub 2014 Jun 19.

42.

Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.

Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, Solt S, Dorman A, Wamwea A, Yager A, Laheru D, Wolfgang CL, Wang J, Hruban RH, Anders RA, Jaffee EM, Zheng L.

Cancer Immunol Res. 2014 Jul;2(7):616-31. doi: 10.1158/2326-6066.CIR-14-0027. Epub 2014 Jun 18.

43.

Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.

De Remigis A, de Gruijl TD, Uram JN, Tzou SC, Iwama S, Talor MV, Armstrong TD, Santegoets SJ, Slovin SF, Zheng L, Laheru DA, Jaffee EM, Gerritsen WR, van den Eertwegh AJ, Le DT, Caturegli P.

Int J Cancer. 2015 Jan 1;136(1):127-37. doi: 10.1002/ijc.28973. Epub 2014 May 28.

44.

Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia.

McAllister F, Bailey JM, Alsina J, Nirschl CJ, Sharma R, Fan H, Rattigan Y, Roeser JC, Lankapalli RH, Zhang H, Jaffee EM, Drake CG, Housseau F, Maitra A, Kolls JK, Sears CL, Pardoll DM, Leach SD.

Cancer Cell. 2014 May 12;25(5):621-37. doi: 10.1016/j.ccr.2014.03.014.

45.

Can we predict mutant neoepitopes in human cancers for patient-specific vaccine therapy?

Lutz ER, Jaffee EM.

Cancer Immunol Res. 2014 Jun;2(6):518-21. doi: 10.1158/2326-6066.CIR-14-0041. Epub 2014 May 2. Review. No abstract available.

46.

Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice.

Black CM, Armstrong TD, Jaffee EM.

Cancer Immunol Res. 2014 Apr;2(4):307-19. doi: 10.1158/2326-6066.CIR-13-0145. Epub 2014 Jan 17.

47.

A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW Jr, Hassan R, Armstrong TD, Jaffee EM.

Gastroenterology. 2014 Jun;146(7):1784-94.e6. doi: 10.1053/j.gastro.2014.02.055. Epub 2014 Mar 6.

48.

Fusion protein of mutant B7-DC and Fc enhances the antitumor immune effect of GM-CSF-secreting whole-cell vaccine.

Kojima M, Murata S, Mekata E, Takebayashi K, Jaffee EM, Tani T.

J Immunother. 2014 Apr;37(3):147-54. doi: 10.1097/CJI.0000000000000025.

49.

Vaccine therapy for pancreatic cancer.

Salman B, Zhou D, Jaffee EM, Edil BH, Zheng L.

Oncoimmunology. 2013 Dec 1;2(12):e26662. Epub 2013 Oct 22. Review.

50.

Tumor immunology: multidisciplinary science driving basic and clinical advances.

Keenan BP, Jaffee EM, Armstrong TD.

Cancer Immunol Res. 2013 Jul;1(1):16-23.

Supplemental Content

Loading ...
Support Center